Hesong Han

Hesong Han

Auto-generated profile, based on publicly available information

Hesong Han

Innovative Genomics Institute, University of California, Berkeley, Berkeley, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
SZSheng Zhao
Sheng Zhao
KGKewa Gao
Kewa Gao
HHHesong Han
Hesong Han
MSMichael Stenzel
Michael Stenzel
BYBoyan Yin
Boyan Yin
Niren MurthyNiren Murthy
Niren Murthy

20 September 2023 in Biochemistry
Verified
Journal Article
Closed access
JTJan Tuma
Jan Tuma
YCYu-Ju Chen
Yu-Ju Chen
MCMichael G. Collins
Michael G. Collins
APAbhik Paul
Abhik Paul
JLJie Li
Jie Li
HLHye Young Lee
Hye Young Lee

24 October 2024 in ACS Nano
Verified
Journal Article
Open access
KGKewa Gao
Kewa Gao
HHHesong Han
Hesong Han
MCMatileen G. Cranick
Matileen G. Cranick
SZSheng Zhao
Sheng Zhao
SXShanxiu Xu
Shanxiu Xu
Aijun WangAijun Wang
Aijun Wang
In utero gene editing with mRNA-based therapeutics has the potential to revolutionize the treatment of neurodevelopmental disorders. However, a critical bottleneck in clinical application has been the lack of mRNA delivery vehicles that can efficiently transfect cells in the brain. In this report, we demonstrate that in utero intracerebroventricular (ICV) injection of densely PEGylated lipid nanoparticles (ADP-LNPs) containing an acid-degradable PEG-lipid can safely and effectively deliver mRNA for gene editing enzymes to the fetal mouse brain, resulting in successful transfection and editing of brain cells. ADP-LNPs containing Cre mRNA transfected 30% of the fetal brain cells in Ai9 mice and had no detectable adverse effects on fetal development and postnatal growth. In addition, ADP-LNPs efficiently transfected neural stem and progenitor cells in Ai9 mice with Cre mRNA, which subsequently proliferated and caused over 40% of the cortical neurons and 60% of the hippocampal neurons to be edited in treated mice 10 weeks after birth. Furthermore, using Angelman syndrome, a paradigmatic neurodevelopmental disorder, as a disease model, we demonstrate that ADP-LNPs carrying Cas9 mRNA and gRNA induced indels in 21% of brain cells within 7 days postpartum, underscoring the precision and potential of this approach. These findings demonstrate that LNP/mRNA complexes have the potential to be a transformative tool for in utero treatment of neurodevelopmental disorders and set the stage for a frontier in treating neurodevelopmental disorders that focuses on curing genetic diseases before birth.

26 September 2025 in Science Advances
Verified
Journal Article
Open access
QGQiang Gao
Qiang Gao
YGYunxia Gao
Yunxia Gao
YCYingui Cao
Yingui Cao
HXHaiting Xu
Haiting Xu
YMYa Ma
Ya Ma
BXBo Xiao
Bo Xiao
The clinical application of CRISPR-Cas9 remains limited by delivery challenges, particularly for oral administration. Lysine-specific demethylase 1 ( Lsd1 ) plays a key role in colonic inflammation and tumorigenesis. Here, we developed an oral genome-editing platform (TPGS-RNP@LNP), where Lsd1 -targeting ribonucleoproteins (RNPs) were encapsulated in mulberry leaf lipid nanoparticles (LNPs) and formulated with d -α-tocopherol polyethylene glycol succinate (TPGS). TPGS reinforced the lipid bilayer of LNPs, enhanced gastrointestinal stability, and facilitated colonic mucus penetration. Upon the galactose receptor–mediated endocytosis of TPGS-RNP@LNPs by macrophages, their fusion with the endosomal membrane and the presence of nuclear localization signals ensured the nuclear delivery of RNPs. TPGS-RNP@LNPs achieved 59.7% Lsd1 editing efficiency in macrophages, surpassing the commercial CRISPRMAX (43.0%). Oral TPGS-RNP@LNPs promoted H3K4 methylation to modulate epigenetic states, achieving inflammation mitigation, epithelial barrier restoration, and retardation of colitis and its associated tumorigenesis. As an LNP-based oral RNP delivery system, TPGS-RNP@LNPs provide a promising platform for precise treatment of colorectal diseases.

3 June 2013 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
BHBifang He
Bifang He
CMCanquan Mao
Canquan Mao
BRBeibei Ru
Beibei Ru
HHHesong Han
Hesong Han
PZPeng Zhou
Peng Zhou
Jian HuangJian Huang
Jian Huang
Metuximab is the generic name of Licartin, a new drug for radioimmunotherapy of hepatocellular carcinoma. Although it is known to be a mouse monoclonal antibody against CD147, the complete epitope mediating the binding of metuximab to CD147 remains unknown. We panned the Ph.D.-12 phage display peptide library against metuximab and got six mimotopes. The following bioinformatics analysis based on mimotopes suggested that metuximab recognizes a conformational epitope composed of more than 20 residues. The residues of its epitope may include T28, V30, K36, L38, K57, F74, D77, S78, D79, D80, Q81, G83, S86, N98, Q100, L101, H102, G103, P104, V131, P132, and K191. The homology modeling of metuximab and the docking of CD147 to metuximab were also performed. Based on the top one docking model, the epitope was predicted to contain 28 residues: AGTVFTTV (23–30), I37, D45, E84, V88, EPMGTANIQLH (92–102), VPP (131–133), Q164, and K191. Almost half of the residues predicted on the basis of mimotope analysis also appear in the docking result, indicating that both results are reliable. As the predicted epitopes of metuximab largely overlap with interfaces of CD147-CD147 interactions, a structural mechanism of metuximab is proposed as blocking the formation of CD147 dimer.

3 November 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
GNGabriel Neiman
Gabriel Neiman
MCMauro W. Costa
Mauro W. Costa
HHHesong Han
Hesong Han
SZSheng Zhao
Sheng Zhao
TNTammy K. Ng
Tammy K. Ng
KHKevin E. Healy
Kevin E. Healy